Could Artificial Intelligence Eradicate Cancer and Diseases Within a Decade?

Anthropic CEO Dario Amodei suggested that with artificial intelligence accelerating biological research, cancer, Alzheimer's, heart diseases, and mental illnesses could be eliminated in less than a decade. While similar optimistic predictions have been voiced by Elon Musk and Google's Demis Hassabis, pharmaceutical executives and experts emphasize that these targets are not realistic.

Anthropic CEO Dario Amodei, heading the company that produces the AI named Claude, stated in remarks that if artificial intelligence is used correctly, problems unsolved for a millennium could be resolved in an age of miracles. Amodei expressed that difficult diseases affecting millions of families, such as cancer and Alzheimer's, will become relics of the past in less than a decade. Similarly, Elon Musk claimed that thanks to artificial intelligence, all of humanity could access the highest level of healthcare currently enjoyed by US presidents; whereas Google's AI leader Demis Hassabis pointed to protein structure mapping successes like AlphaFold, suggesting that the decade-long drug discovery process could be reduced to weeks and bring an end to diseases.

However, experts and corporate executives involved in the drug development process approach this optimistic timeline with skepticism. Vertex Pharmaceuticals Chairman Jeff Leiden criticized these predictions, stating that they had tested about 50 artificial intelligence companies and that, despite screening ten thousand compounds, no single AI tool had produced a functioning drug. Pharmaceutical leaders emphasize that finding a promising molecule on a computer screen is only the first step; testing these molecules in laboratories, animal models, and human clinical trials constitutes the largest part of the 10-12 year development process. Critics such as cognitive scientist Gary Marcus and cardiologist Eric Topol also state that current artificial intelligence models lack deep causal and biological understanding, that as of 2026 no drug designed by AI has reached full clinical approval, and that such claims could push public expectations beyond reality.